Polarean Imaging’s (POLX) corporate Rating Reaffirmed at Northland Capital Partners

Polarean Imaging (LON:POLX)‘s stock had its “corporate” rating reiterated by investment analysts at Northland Capital Partners in a report issued on Friday, July 27th.

Shares of POLX stock remained flat at $GBX 14.88 ($0.19) on Friday. The stock had a trading volume of 25,000 shares.

Polarean Imaging Company Profile



Polarean Imaging Plc operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The company manufactures and services noble gas polarizer devices and ancillary instruments with a special focus on pulmonary imaging. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of polarized Xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally down to the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach.

Featured Story: Average Daily Trade Volume – What It Means In Stock Trading

Receive News & Ratings for Polarean Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polarean Imaging and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Leave a Reply